4,6-dihydroxy-2-[(2-phenyl-1H-indol-3-yl)methylene]-1-benzofuran-3(2H)-one | 1200527-86-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 4,6-dihydroxy-2-[(2-phenyl-1H-indol-3-yl)methylene]-1-benzofuran-3(2H)-one
• 英文别名: 4,6-dihydroxy-2-[(2-phenyl-1H-indol-3-yl)methylidene]-1-benzofuran-3-one
• CAS: 1200527-86-1
• 化学式: C₂₃H₁₅NO₄
• 分子量: 369.376
• InChiKey: FDZLVAKABOAMEY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  28
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  82.6
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4,6-二羟基-3-苯并呋喃酮 、 2-苯基吲哚-3-甲醛 在 盐酸 作用下， 以 乙醇 、 水 为溶剂， 生成 4,6-dihydroxy-2-[(2-phenyl-1H-indol-3-yl)methylene]-1-benzofuran-3(2H)-one
  参考文献：
  名称：

  Novel benzofuran-3-one indole inhibitors of PI3 kinase-α and the mammalian target of rapamycin: Hit to lead studies

  摘要：

  A series of benzofuran-3-one indole phosphatidylinositol-3-kinases (PI3K) inhibitors identified via HTS has been prepared. The optimized inhibitors possess single digit nanomolar activity against p110 alpha (PI3K-alpha), good pharmaceutical properties, selectivity versus p110 gamma (PI3K-gamma), and tunable selectivity versus the mammalian target of rapamycin ( mTOR). Modeling of compounds 9 and 32 in homology models of PI3K-alpha and mTOR supports the proposed rationale for selectivity. Compounds show activity in multiple cellular proliferation assays with signaling through the PI3K pathway confirmed via phospho-Akt inhibition in PC-3 cells. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.02.082

文献信息

• Novel benzofuran-3-one indole inhibitors of PI3 kinase-α and the mammalian target of rapamycin: Hit to lead studies
  作者：Matthew G. Bursavich、Natasja Brooijmans、Lawrence Feldberg、Irwin Hollander、Stephen Kim、Sabrina Lombardi、Kaapjoo Park、Robert Mallon、Adam M. Gilbert

  DOI：10.1016/j.bmcl.2010.02.082

  日期：2010.4

  A series of benzofuran-3-one indole phosphatidylinositol-3-kinases (PI3K) inhibitors identified via HTS has been prepared. The optimized inhibitors possess single digit nanomolar activity against p110 alpha (PI3K-alpha), good pharmaceutical properties, selectivity versus p110 gamma (PI3K-gamma), and tunable selectivity versus the mammalian target of rapamycin ( mTOR). Modeling of compounds 9 and 32 in homology models of PI3K-alpha and mTOR supports the proposed rationale for selectivity. Compounds show activity in multiple cellular proliferation assays with signaling through the PI3K pathway confirmed via phospho-Akt inhibition in PC-3 cells. (C) 2010 Elsevier Ltd. All rights reserved.